European Lung Cancer Conference (ELCC)

Taletrectinib can produce durable responses in patients with ROS1-positive non-small cell lung cancer, a phase 2 trial suggests.

Combination regimens including tusamitamab ravtansine have demonstrated activity in a phase 2 study of patients with CEACAM5+ non-small cell lung cancer.

Amivantamab can provide a long-term benefit in NSCLC patients with EGFR exon 20 insertions whose disease progressed on platinum-based chemotherapy, a study suggests.

Upfront osimertinib can reduce the risk of brain progression, when compared with gefitinib followed by osimertinib, in advanced EGFR-mutant NSCLC, a study suggests.

Health-related quality of life was generally superior with immunotherapy plus chemotherapy vs chemotherapy alone.

Disease-free survival was better with atezolizumab than with best supportive care.

Overall survival was significantly longer for patients who received sintilimab plus chemotherapy than for those who received placebo plus chemotherapy.

Adding ipilimumab to pembrolizumab did not improve survival outcomes.

Furmonertinib improved progression-free survival and appeared safer than gefitinib in a phase 3 trial.

Camrelizumab improved overall survival, even when adjusting for crossover.